The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.

Libtayo shows robust growth in specific cancers, although it faces stiff competition in broader indications, highlighting Regeneron’s ability to develop blockbuster drugs. Regeneron appears ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

One patient with Merkel cell carcinoma (MCC) achieved a durable complete response with 15 milligrams per kilogram (mg/kg) solnerstotug and Libtayo (cemiplimab) and remains on treatment at 42 or more ...

Despite these challenges, Regeneron's other drugs, particularly Dupixent and Libtayo, show promise for future growth and revenue generation. Given the current uncertainties and risks, I rate ...

Celles-ci privilégieraient l’hypothèse d’une fuite d’un laboratoire chinois, avec une probabilité de 80 à 95 pour cent. L’article raconte comment le service fédéral de renseignement ...

Panelists discuss how the five-year prognosis for advanced non-small cell lung cancer (NSCLC) has improved with PD-1 inhibitors, showing promising overall survival (OS) and progression-free survival ...

Panelists discuss how over the last five years, immunotherapy, particularly PD-1 inhibitors, has revolutionized advanced non-small cell lung cancer (NSCLC) treatment, offering promising first-line ...

After hours: 20 March at 19:51:30 GMT-4 Loading Chart for REGN ...